Development of a target-capture NGS assay for use in molecular-based research of myeloid measurable residual disease

In this poster, Oxford Gene Technology (OGT) highlights the increasing role of molecular methods, specifically next-generation sequencing (NGS), in detecting measurable residual disease (MRD) in conditions like acute myeloid leukemia (AML). While real-time qPCR (RQ-PCR) and digital droplet PCR (ddPCR) are highly sensitive, they have limitations in detecting multiple targets in a single assay. NGS overcomes this limitation by allowing the evaluation of many genes and variant types in a single assay. OGT has developed a target-capture NGS approach to support researchers in studying molecular-based MRD monitoring in myeloid malignancies, offering improved accuracy and cost-effectiveness.